Managing the TME to improve the efficacy of cancer therapy
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) influences tumor growth, metastatic spread and response to treatment. Often immunosuppression, mediated by the TME, impairs a beneficial response. The complexity of the tumor composition challenges our abilities to design new and more effective therapies. Going forward we will need to ‘manage’ the content and or functionality of the TME to improve treatment outcomes. Currently, several different kinds of treatments are available to patients with cancer: there are the traditional approaches of chemotherapy, radiation and surgery; there are targeted agents that inhibit kinases associated with oncogenic pathways; there are monoclonal antibodies that target surface antigens often delivering toxic payloads or cells and finally there are antibodies and biologics that seek to overcome the immunosuppression caused by elements within the TME. How each of these therapies interact with the TME is currently under intense and widespread investigation. In this review we describe how the TME and its immunosuppressive components can influence both tumor progression and response to treatment focusing on three particular tumor types, classic Hodgkin Lymphoma (cHL), Pancreatic Ductal Adenocarcinoma (PDAC) and Glioblastoma Multiforme (GBM). And, finally, we offer five approaches to manipulate or manage the TME to improve outcomes for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“IL-4, IL-13 and M-CSF attract myeloid cells and polarize macrophages into MDSC and TAMs (46).”
BackgroundThe Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Extracellular DNA traps promote thrombosis
Fuchs, T. A., Brill, A., Duerschmied, D., Schatzberg, D., Monestier, M., Myers, D. D., Wrobleski, S. K., Wakefield, T. W., Hartwig, J. H., & Wagner, D. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005743107 · Cited by 2,492
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“For example, the interaction between the tumoral cells and the extracellular matrix (ECM) through the binding with its components (collagen, fibronectin, and laminin) is responsible for the cell adhesion-mediated drug resistance (CAM-DR), that mediates the resistance to radiotherapy and antibody-based receptor tyrosin…”
BackgroundStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · cited 1×
“Is this fashion cells with the potential to fight tumor growth are altered and become part of the suppressive landscape (14).”
BackgroundTherapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,625
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950 · cited 1×
“CAFs participate in active cross-talk with cancer cells within the tumour microenvironment (47) and contribute to drug resistance (47).”
BackgroundTumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.010 · Cited by 850
Intra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., & Golab, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 424
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 359
Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 337
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Biasci, D., Smoragiewicz, M., Connell, C. M., Wang, Z., Gao, Y., Thaventhiran, J. E. D., Basu, B., Magiera, L., Johnson, T. I., Bax, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013644117 · Cited by 262
Connors, J. M., Cozen, W., Steidl, C., Carbone, A., Hoppe, R. T., Flechtner, H.-H., & Bartlett, N. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0189-6 · Cited by 230
Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients
Wu, W.-C., Sun, H.-W., Chen, H.-T., Liang, J., Yu, X.-J., Wu, C., Wang, Z., & Zheng, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320753111 · Cited by 227
Aoki, T., Chong, L. C., Takata, K., Milne, K., Hav, M., Colombo, A., Chavez, E. A., Nissen, M., Wang, X., Miyata-Takata, T., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0680 · Cited by 223
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01916-x · Cited by 212
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C., Wang, D., et al. (2021) · Science · doi:10.1126/science.aba2609 · Cited by 199
Targeting the tumor microenvironment: JAK-STAT3 signaling
Bournazou, E., & Bromberg, J. (2013) · JAK-STAT · doi:10.4161/jkst.23828 · Cited by 189
Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1490 · Cited by 188
Powell, D. J., Felipe-Silva, A., Merino, M. J., Ahmadzadeh, M., Allen, T., Levy, C., White, D. E., Mavroukakis, S., Kreitman, R. J., Rosenberg, S. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4919 · Cited by 166
Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0841 · Cited by 164
Grossman, J. G., Nywening, T. M., Belt, B. A., Panni, R. Z., Krasnick, B. A., DeNardo, D. G., Hawkins, W. G., Goedegebuure, S. P., Linehan, D. C., & Fields, R. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1470729 · Cited by 135
Myeloid Cells during Viral Infections and Inflammation
Stegelmeier, A. A., van Vloten, J. P., Mould, R. C., Klafuric, E. M., Minott, J. A., Wootton, S. K., Bridle, B. W., & Karimi, K. (2019) · Viruses · doi:10.3390/v11020168 · Cited by 128
Onda, M., Kobayashi, K., & Pastan, I. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820388116 · Cited by 124
Mitchell, D. A., Cui, X., Schmittling, R. J., Sanchez-Perez, L. A., Snyder, D. J., Congdon, K. L., Archer, G. E., Desjardins, A., Friedman, A. H., Friedman, H. S., et al. (2011) · Blood · doi:10.1182/blood-2011-02-334565 · Cited by 114
Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape
Sarkar, T., Dhar, S., & Sa, G. (2021) · Current Research in Immunology · doi:10.1016/j.crimmu.2021.08.002 · Cited by 114
Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01120-y · Cited by 106
VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice
Ferjancic, S., Gil‐Bernabé, A. M., Hill, S. A., Allen, P. D., Richardson, P., Sparey, T. J., Savory, E., McGuffog, J., & Muschel, R. J. (2013) · Blood · doi:10.1182/blood-2012-08-449819 · Cited by 104
Sun, P., Zhang, X., Wang, R.-J., Ma, Q., Xu, L., Wang, Y., Liao, H., Wang, H.-L., Hu, L., Kong, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003093 · Cited by 100
Wang, Z., Moresco, P., Yan, R., Li, J., Gao, Y., Biasci, D., Yao, M., Pearson, J., Hechtman, J. F., Janowitz, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119463119 · Cited by 93
Gaggero, S., Witt, K., Carlsten, M., & Mitra, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621225 · Cited by 85
Ugurel, S., Spassova, I., Wohlfarth, J., Drusio, C., Cherouny, A., Melior, A., Sucker, A., Zimmer, L., Ritter, C., Schadendorf, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02341-9 · Cited by 84
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
Park, J., Kim, C. G., Shim, J., Kim, J. H., Lee, H., Lee, J. E., Kim, M. H., Haam, K., Jung, I., Park, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1525243 · Cited by 77
The Role of Myeloid Cells in GBM Immunosuppression
Lin, Y.-J., Wu, C. Y.-J., Wu, J. Y., & Lim, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887781 · Cited by 69
Tumino, N., Besi, F., Martini, S., Pace, A. L. D., Munari, E., Quatrini, L., Pelosi, A., Fiore, P. F., Fiscon, G., Paci, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803014 · Cited by 63
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
Staniszewska, A. D., Armenia, J., King, M. A., Michaloglou, C., Reddy, A., Singh, M., Martin, M. S., Prickett, L. B., Wilson, Z., Proia, T. A., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2083755 · Cited by 63
Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
Wang, S., Yang, Y., Ma, P., Huang, H., Tang, Q., Miao, H., Fang, Y., Jiang, N., Li, Y., Zhu, Q., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.019 · Cited by 62
Wang, Z., Moresco, P., Yan, R., Li, J., Gao, Y., Biasci, D., Yao, M., Pearson, J., Hechtman, J. F., Janowitz, T., et al. (2022) · Apollo (University of Cambridge) · doi:10.17863/cam.81675 · Cited by 61
Mikkilineni, L., Whitaker‐Menezes, D., Domingo‐Vidal, M., Sprandio, J. D., Avena, P., Cotzia, P., Dulau‐Florea, A., Gong, J. Z., Uppal, G. K., Zhan, T., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.003 · Cited by 57
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Knudson, K. M., Hicks, K. C., Ozawa, Y., Schlom, J., & Gameiro, S. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000493 · Cited by 53
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages
Bellora, F., Dondero, A., Corrias, M. V., Casu, B., Regis, S., Caliendo, F., Moretta, A., Cazzola, M., Elena, C., Vinti, L., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601695 · Cited by 44
Swierczak, A., & Pollard, J. W. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038026 · Cited by 42
Good, L., Benner, B. N., & Carson, W. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02908-5 · Cited by 42
Intravital microscopy in mammalian multicellular organisms
Ebrahim, S., & Weigert, R. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.03.015 · Cited by 38
Zomer, A., Croci, D., Kowal, J., van Gurp, L., & Joyce, J. A. (2022) · iScience · doi:10.1016/j.isci.2022.104570 · Cited by 37
Immune Modulation in Hematologic Malignancies
Dhodapkar, M. V., & Dhodapkar, K. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.009 · Cited by 32
Ng, S., Deng, J., Chinnadurai, R., Yuan, S., Pennati, A., & Galipeau, J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0386 · Cited by 25
Simon, N. C., Antignani, A., Hewitt, S. M., Gadina, M., Alewine, C., & FitzGerald, D. J. (2019) · JCI Insight · doi:10.1172/jci.insight.123281 · Cited by 23
Self-citationNovel Immunoregulatory Functions of IL-18, an Accomplice of TGF-β1
Casu, B., Dondero, A., Regis, S., Caliendo, F., Petretto, A., Bartolucci, M., Bellora, F., Bottino, C., & Castriconi, R. (2019) · Cancers · doi:10.3390/cancers11010075 · Cited by 22
Selective Autophagy Conceals the Enemy: Why Cytotoxic T Cells Don’t (MH)C Pancreatic Cancer
Božić, M., & Wilkinson, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.009 · Cited by 6
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A.-H. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02357-z · Cited by 239
Metadata
- Authors
- Bilotta, M. T., Antignani, A., & Fitzgerald, D. J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-10-20
- Volume
- 13
- Pages
- 954992-954992
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4306946959
- Cited by
- 309
- References
- 66
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.